🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Rachel W. Linnemann

Emory University

ORCID: 0000-0002-6839-0936

Also affiliated with Children's Healthcare of Atlanta

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile
0Author DataRank

Indexed papers

0in pilot corpus
datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 11 papers. Top paper: “Discontinuation versus continuation of hypertonic saline or dornase alfa in modulator treated people with cystic fibrosis (SIMPLIFY): results from two parallel, multicentre, open-label, randomised, controlled, non-inferiority trials”.

Discontinuation versus continuation of hypertonic saline or dornase alfa in modulator treated people with cystic fibrosis (SIMPLIFY): results from two parallel, multicentre, open-label, randomised, controlled, non-inferiority trials

The Lancet Respiratory Medicine(2022)10.1016/s2213-2600(22)00434-9
N/A
3.9DataRank · unranked
127 citations

Félix Ratjen, Renee Russell, Scott H. Donaldson, Kristin A. Riekert, Gregory S. Sawicki +91 more

Vanzacaftor–tezacaftor–deutivacaftor versus elexacaftor–tezacaftor–ivacaftor in individuals with cystic fibrosis aged 12 years and older (SKYLINE Trials VX20-121-102 and VX20-121-103): results from two randomised, active-controlled, phase 3 trials

The Lancet Respiratory Medicine(2025)10.1016/s2213-2600(24)00411-9
N/A
1.9DataRank · unranked
95 citations

Lael M. Yonker, F. Vermeulen, Dario Prais, Rachel W. Linnemann, Aaron Trimble +92 more

Evaluation of elexacaftor–tezacaftor–ivacaftor treatment in individuals with cystic fibrosis and CFTRN1303K in the USA: a prospective, multicentre, open-label, single-arm trial

The Lancet Respiratory Medicine(2024)10.1016/s2213-2600(24)00205-4
N/A
1.1DataRank · unranked
28 citations

Rachel W. Linnemann, Rachel Rich, Ashleigh Streby, Brian Buehler, Eric Hunter +14 more

106 Impact of discontinuing hypertonic saline and dornase alfa in people with cystic fibrosis established on elexacaftor-tezacaftor-ivacaftor: A SIMPLIFY ancillary study

Journal of Cystic Fibrosis(2023)10.1016/s1569-1993(23)01041-x
N/A
0DataRank · unranked
1 citations

Alex H. Gifford, Margaret Kloster, Richard Russell, Andrew T. Braun, Ronald L. Gibson +9 more

280 Induced pluripotent stem cell–based airway epithelial platform for investigating personalized responses to CFTR modulators

Journal of Cystic Fibrosis(2023)10.1016/s1569-1993(23)01208-0
N/A
0DataRank · unranked
0 citations

András Rab, Shunji Suzuki, Richard Bertrand, Stefan Winkler, S. Ponnaluri +12 more

242 An open-label trial to evaluate elexacaftor-tezacaftor-ivacaftor and induced pluripotent stem cell–derived model systems in individuals with residual CFTR activity

Journal of Cystic Fibrosis(2023)10.1016/s1569-1993(23)01171-2
N/A
0DataRank · unranked
0 citations

George M. Solomon, Shingo Suzuki, András Rab, C. Barillà, Arlene A. Stecenko +11 more

Impact of Discontinuing Both Hypertonic Saline and Dornase Alfa after Elexacaftor-Tezacaftor-Ivacaftor in Cystic Fibrosis

Annals of the American Thoracic Society(2024)10.1513/annalsats.202404-366oc
N/A
0DataRank · unranked
10 citations

Alex H. Gifford, Margaret Kloster, Renee Russell, Andrew T. Braun, Ronald L. Gibson +11 more

CFTR Variant Frequencies and Newborn Screening Panel Performance in the Diverse CF Population Receiving Care in the State of Georgia

International Journal of Neonatal Screening(2025)10.3390/ijns11040085
N/A
0DataRank · unranked
0 citations

Brittany A. Truitt, Andrew Jergel, Shasha Bai, Kathleen McKie, Rossana Sanchez Russo +3 more

Evaluating Georgia’s Cystic Fibrosis Newborn Screening Algorithm to Inform Improvement Recommendations

International Journal of Neonatal Screening(2025)10.3390/ijns11040087
N/A
0DataRank · unranked
0 citations

Eileen Barr, Angela Wittenauer, Andrew Jergel, Shasha Bai, Rossana Sanchez Russo +4 more

Serum anti-PAD4 autoantibodies are present in cystic fibrosis children and increase with age and lung disease severity

Autoimmunity(2022)10.1080/08916934.2021.2021193
N/A
0DataRank · unranked
10 citations

Ruchi Yadav, Chao Zhang, Demba Sarr, Balázs Rada, Arlene A. Stecenko +1 more

Development of a Cystic Fibrosis Primary Palliative Care Intervention: Qualitative Analysis of Patient and Family Caregiver Preferences

Journal of Patient Experience(2023)10.1177/23743735231161486
N/A
0DataRank · unranked
2 citations

Lara Dhingra, Stephanie DiFiglia, Jennifer Polo, Russell K. Portenoy, Janice Wang +17 more